Pulse Pharmaceuticals Pvt Ltd.

MOUNT PROSPECT, Ill., Sept. 10, 2024 /PRNewswire/ -- Walgreens has joined Pulse by NABP™, the new digital platform from National Association of Boards of Pharmacy® (NABP®) that will bring visibility to the drug supply chain and protect patients from counterfeit or substandard prescription medications. Walgreens will use Pulse to assist with Drug Supply Chain Security Act (DSCSA) compliance and to help ensure its prescription medication suppliers are appropriately licensed. Continue Reading DSCSA is a federal law that was enacted in 2013 to improve the safety of the pharmaceutical supply chain and to help prevent harmful drugs from entering the market. The law requires all members of the pharmaceutical supply chain to ensure they are doing business with trading partners that are authorized in accordance with federal law. Walgreens will use Pulse to assist with DSCSA compliance and protect patients from counterfeit prescription medications. Post this Pulse will help ensure that only legitimate and authorized trading partners can provide medications to Walgreens' patients. "Walgreens is committed to protecting the health and safety of our patients," said John Colaizzi, PharmD, FNJPhA, vice president of pharmacy practice at Walgreens. "Joining Pulse will be an additional DSCSA compliance tool that will help Walgreens ensure that the medications our patients take are legitimate." "We are pleased to welcome Walgreens to Pulse," said Lemrey "Al" Carter, PharmD, MS, RPh, executive director/secretary of NABP. "Walgreens' participation in Pulse will help to strengthen the security of the pharmaceutical supply chain and help protect Walgreens' patients." NABP is rolling out the Pulse platform to certain users in the supply chain. After this initial onboarding, NABP will provide free registration on the Pulse platform for any member of the prescription drug supply chain to facilitate interoperability, as required by DSCSA. Learn more about Pulse and DSCSA compliance at . About NABP NABP is the independent, international, and impartial 501(c)(3) nonprofit Association that assists its state member boards and jurisdictions in protecting the public health. NABP was established in 1904 to assist the state boards of pharmacy in creating uniform education and licensure standards. Today, we help support patient and prescription drug safety through examinations that assess pharmacist competency, pharmacist licensure transfer and verification services, and various pharmacy accreditation and inspection programs. About Walgreens Walgreens () is included in the U.S. Retail Pharmacy and U.S. Healthcare segments of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), an integrated healthcare, pharmacy and retail leader. True to its purpose of "more joyful lives through better health," Walgreens has a more than 120-year heritage of caring for communities and providing trusted pharmacy services, and today is playing a greater role as an independent partner of choice offering healthcare services that improve care, lower costs, and help patients. Operating nearly 9,000 retail locations across the U.S. and Puerto Rico, Walgreens is proud to serve nearly 9 million customers and patients daily. The company's pharmacists are playing a more critical role in healthcare than ever before, providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for some of the nation's most underserved populations. Walgreens offers customers and patients a true omnichannel experience, with fully integrated physical and digital platforms designed to deliver high-quality products and healthcare services. Within the U.S. Healthcare segment, Walgreens portfolio also includes businesses in primary care, multi-specialty, post-acute care, urgent care, specialty pharmacy services, population health and provider enablement. Media Contact: [email protected] SOURCE National Association of Boards of Pharmacy WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The FDA previously cleared Pulse's CellFX hardware for needle-based soft tissue ablation. Now it will pursue a PMA in atrial fibrillation after raising $83 million in a Nasdaq offering. After developing its pulsed field ablation technology for use outside cardiology, Pulse Biosciences has now received a boost from the FDA with a breakthrough designation to help adapt its approach to treat irregular heart rhythms.  Earlier this year, the company’s CellFX hardware collected a 510(k) clearance from the agency for the needle-based, surgical ablation of soft tissues. Like all pulsed field ablation systems, it employs ultra-fast, fluctuating electric fields that can disrupt troublesome cells without generating the heat that can spread to harm adjacent organs. The breakthrough designation comes just days after the company reported that it raised more than $83 million through a rights offering on the Nasdaq.  Now, Pulse Biosciences said it plans to pursue a premarket approval for its device in atrial fibrillation, as opposed to a 510(k) green light, with the ability to be used alongside other open heart surgeries and deliver a total application time of under 2 seconds.  A first-in-human study in the Netherlands is slated for later this year, while a U.S. pivotal trial is set for 2025. The company said its platform was also designed to one day be used with catheter-based therapies. “The Breakthrough Device Designation granted by the FDA is an exciting milestone for Pulse. It emphasizes the unique potential benefits of nanosecond PFA,” said President and CEO Burke Barrett, who joined Pulse Biosciences as chief in May. Barrett previously spent 18 years at the electrophysiology developer CardioFocus. “I’ve spent the majority of my career working closely with electrophysiologists and introducing them to novel technologies, and I believe that CellFX nsPFA energy has the potential to advance the standard of care for the treatment of atrial fibrillation and additional disease states,” he said in a statement at the time. That month also saw the company report its first U.S. procedure with the CellFX percutaneous electrode system, with a benign nodule ablation performed at the Sarasota Memorial Hospital’s Thyroid and Parathyroid Center in Florida.

Singapore, 25 May 2024 – In a First-In-Singapore collaboration, leading RNA technology company Mirxes and PULSE TCM, a renowned provider of traditional Chinese Medicine (TCM) services, today launched the holistic “East Meets West” Community Health Screening Pilot at Bukit Gombak. Witnessed by Ms Low Yen Ling, Senior Minister of State, Ministry of Culture, Community and Youth, Ministry of Trade and Industry, Mayor of South West District and Grassroots Adviser to Bukit Gombak Grassroots Organisations, this pilot represents a novel approach towards integrating contemporary Western precision diagnostic technology with Eastern TCM wisdom, aimed at creating an integrated approach to preventive and personalised healthcare for a Healthier Singapore. Complementary Western and Eastern Medicines in disease early detection and prevention 2. In Singapore, cancer and chronic diseases like cardiovascular and metabolic conditions are major contributors of healthcare burden. These diseases share common risk factors stemming from lifestyle and environment. Factors like aging, smoking, alcohol consumption, obesity, and infections all contribute to cellular and molecular changes that drive the development and progression of these diseases. 3. Contemporary Western precision diagnostic technologies, such as Mirxes’ GASTROClear blood test, leverage advanced molecular detection to identify abnormalities in RNA and DNA. This allows for early disease detection, often before symptoms arise. Early and precise diagnosis enables timely interventions, and potentially improved patient outcomes and significant cost savings. 4. The Eastern TCM concept of “治未病”, which translates to “treating before illness arises”, takes prevention a step further by intervening before complex diseases like cancer develop. TCM also uses the concept of “body constitution”, which refers to a person’s inherent physical and physiological tendencies, to personalise risk assessment and prevention. TCM practitioners consider body constitution when diagnosing and treating patients, tailoring approaches based on an individual’s unique balance of Yin, Yang, Qi (Energy), and Blood. By understanding one’s body constitution, TCM can promote overall health, prevent disease, and develop personalised treatment plans. Bridging Western and Eastern Medical Paradigms 5. This collaboration is committed to bridging Eastern and Western medical paradigms, leveraging the best of both. It also marks a new frontier for preventive health screening in Singapore, by facilitating an earlier and better understanding of individual health profiles. TCM empowers individuals to gain early insights into their body constitution, encouraging proactive measures to maintain health and potentially prevent certain diseases and cancers. Western precision diagnostics complements this by detecting complex and serious diseases early before symptom occurs. Through this pilot, Mirxes and PULSE TCM hope to synergise the best of two worlds and explore the potential of a joint study to evaluate and establish the effectiveness of a combined “East meets West” health management programme. 6. “We are thrilled to introduce this innovative collaboration that brings together the best of Western and Eastern medicines,” said Dr Zhou Lihan, Co-Founder and CEO of Mirxes. “At Mirxes, our mission of making healthcare affordable and accessible extends beyond innovation. It also encompasses tailoring healthcare solutions to the unique needs of our customers. By integrating TCM principles alongside our advanced RNA technology, we aspire to provide a more holistic approach to disease early detection and prevention, empowering individuals to take proactive steps towards their well-being.” 7. “We are excited to join forces with Mirxes in this groundbreaking collaboration that bridges the wisdom of Traditional Chinese Medicine with contemporary healthcare technology,” said Mr Nicholas Poh, Founder of PULSE TCM. “At PULSE TCM, we believe in the power of integrating TCM practices into Western medicine, and this partnership exemplifies our commitment.” 8. “East Meets West” Community Health Screening Pilot was held as part of the Bukit Gombak Cares initiative, a constituency wide initiative that focuses on addressing the needs of the residents, from elevating the impact of rising cost of living to improving health and wellness through programmes and activities. The 30 selected residents received a complimentary comprehensive health assessment, undergoing both “western” precision health screening and personalised TCM consultation. TCM physicians also delved into their unique health needs, offering tailored recommendations that include herbal prescriptions and acupoint therapies. About Mirxes Mirxes is a leading RNA technology company that is making cancer early detection solutions accessible on a global scale. Leading the global fight against cancer, our flagship initiative, Project CADENCE (Cancer Detected Early caN be CurEd), leverages our industry-leading RNA technology platform, deep expertise in PCR diagnostics, and population-scale next-generation sequencing (NGS) capabilities to create a blood-based multi-cancer early detection test to alleviate cancer burden, save lives and reduce healthcare costs. Founded in 2014, Mirxes is a high growth company,headquartered in Singapore, producing diagnostic test kits for early disease detection globally and delivering research and clinical testing services for preventive healthcare and precision medicine to key markets in Asia and beyond. About PULSE TCM PULSE TCM aspires to educate the general masses of the long-term benefits of Traditional Chinese Medicine by marrying its modern outlook with time-tested knowledge and expertise. Our clinics and bilingual physicians provide an extensive range of TCM treatments from acupuncture, cupping, and herbal medication to address a variety of conditions and aid in achieving wellness naturally and holistically. Our treatments range from supporting chronic illnesses to alleviating sub-health conditions, as well as programmes for fertility, sports recovery and acne management.